{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:10:09Z","timestamp":1794971409101,"version":"4.9.1"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease (AD) is a devastating neurodegenerative disease and the most prevalent type of dementia characterized by pathological deposition of amyloid-\u03b2 plaques\/deposits and tau tangles within the brain parenchyma. This progressive ailment is featured by irreversible cognitive impairment and memory loss, often misdiagnosed as the consequence of old age in elderlies. Pathologically, synaptic dysfunction occurs at the early stages and then progresses into neurodegeneration with neuronal cell death in later stages. In this review, we aimed to critically discuss and highlight recent advances in the pathological footprints of amyloid-\u03b2 and tau in AD. Specifically, we focused our attention on the interplay and synergistic effects of amyloid-\u03b2 and tau in the pathogenesis of AD. We hope that our paper will provide new insights and perspectives on these pathological features of AD and spark new ideas and directions in AD research and treatment.<\/jats:p>","DOI":"10.1038\/s41419-025-08186-8","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:40:49Z","timestamp":1767969649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Amyloid-\u03b2 and Tau in Alzheimer\u2019s disease: pathogenesis, mechanisms, and interplay"],"prefix":"10.1038","volume":"17","author":[{"given":"Altaf A.","family":"Abdulkhaliq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonglee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef M.","family":"Almoghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johra","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3667-2605","authenticated-orcid":false,"given":"Amir","family":"Ajoolabady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0275-0783","authenticated-orcid":false,"given":"Jun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhad","family":"Bahijri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaakko","family":"Tuomilehto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Borai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Pratico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"8186_CR1","doi-asserted-by":"crossref","unstructured":"Fronza MG, Alves D, Pratic\u00f2 D, Savegnago L. The neurobiology and therapeutic potential of multi-targeting \u03b2-secretase, glycogen synthase kinase 3\u03b2 and acetylcholinesterase in Alzheimer\u2019s disease. Ageing Res Rev 2023;90:102033.","DOI":"10.1016\/j.arr.2023.102033"},{"key":"8186_CR2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41419-022-05153-5","volume":"13","author":"A Ajoolabady","year":"2022","unstructured":"Ajoolabady A, Lindholm D, Ren J, Pratico D. ER stress and UPR in Alzheimer\u2019s disease: mechanisms, pathogenesis, treatments. Cell Death Dis. 2022;13:706.","journal-title":"Cell Death Dis"},{"key":"8186_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118664","volume":"1867","author":"E Lauretti","year":"2020","unstructured":"Lauretti E, Dincer O, Pratic\u00f2 D. Glycogen synthase kinase-3 signaling in Alzheimer\u2019s disease. Biochim Biophys Acta\u2013Mol Cell Res. 2020;1867:118664.","journal-title":"Biochim Biophys Acta\u2013Mol Cell Res"},{"key":"8186_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.tips.2008.09.001","volume":"29","author":"D Pratic\u00f2","year":"2008","unstructured":"Pratic\u00f2 D. Oxidative stress hypothesis in Alzheimer\u2019s disease: a reappraisal. Trends Pharm Sci. 2008;29:609\u201315.","journal-title":"Trends Pharm Sci"},{"key":"8186_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/alz.12220","volume":"17","author":"NN Lyssenko","year":"2021","unstructured":"Lyssenko NN, Pratic\u00f2 D. ABCA7 and the altered lipidostasis hypothesis of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2021;17:164\u201374.","journal-title":"Alzheimer\u2019s Dement"},{"key":"8186_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11813-6","volume":"10","author":"P Jadiya","year":"2019","unstructured":"Jadiya P, Kolmetzky DW, Tomar D, Di Meco A, Lombardi AA, Lambert JP, et al. Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer\u2019s disease. Nat Commun. 2019;10:3885.","journal-title":"Nat Commun"},{"key":"8186_CR7","doi-asserted-by":"crossref","unstructured":"Almkvist O, Basun H, B\u00e4ckman L, Herlitz A, Lannfelt L, Small B, et al. Mild cognitive impairment\u2014an early stage of Alzheimer\u2019s disease? Springer, 1998.","DOI":"10.1007\/978-3-7091-7508-8_3"},{"key":"8186_CR8","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.4103\/1673-5374.332127","volume":"17","author":"AR Roda","year":"2022","unstructured":"Roda AR, Serra-Mir G, Montoliu-Gaya L, Tiessler L, Villegas S. Amyloid-beta peptide and tau protein crosstalk in Alzheimer\u2019s disease. Neural Regen Res. 2022;17:1666.","journal-title":"Neural Regen Res"},{"key":"8186_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0072-9752(07)01219-5","volume":"89","author":"OL L\u00f3pez","year":"2008","unstructured":"L\u00f3pez OL, DeKosky ST. Clinical symptoms in Alzheimer\u2019s disease. Handb Clin Neurol. 2008;89:207\u201316.","journal-title":"Handb Clin Neurol"},{"key":"8186_CR10","first-page":"201","volume":"15","author":"J Chen","year":"2024","unstructured":"Chen J, Chen J-S, Li S, Zhang F, Deng J, Zeng L-H, et al. Amyloid precursor protein: a regulatory hub in Alzheimer\u2019s disease. Aging Dis. 2024;15:201.","journal-title":"Aging Dis"},{"key":"8186_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1124\/molpharm.121.000468","volume":"103","author":"T Hosoi","year":"2023","unstructured":"Hosoi T, Yazawa K, Imada M, Tawara A, Tohda C, Nomura Y, et al. Alkannin attenuates amyloid \u03b2 aggregation and Alzheimer\u2019s disease pathology. Mol Pharm. 2023;103:266\u201373.","journal-title":"Mol Pharm"},{"key":"8186_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther. 2023;8:248.","journal-title":"Signal Transduct Target Ther"},{"key":"8186_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/jnc.12202","volume":"126","author":"L Gu","year":"2013","unstructured":"Gu L, Guo Z. Alzheimer\u2019s A\u03b242 and A\u03b240 peptides form interlaced amyloid fibrils. J Neurochem. 2013;126:305\u201311.","journal-title":"J Neurochem"},{"key":"8186_CR14","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1021\/acs.jpcb.3c01078","volume":"127","author":"X Li","year":"2023","unstructured":"Li X, Yang Z, Chen Y, Zhang S, Wei G, Zhang L. Dissecting the molecular mechanisms of the co-aggregation of A\u03b240 and A\u03b242 peptides: a REMD simulation study. J Phys Chem B. 2023;127:4050\u201360.","journal-title":"J Phys Chem B"},{"key":"8186_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"G-f Chen","year":"2017","unstructured":"Chen G-f, Xu T-h, Yan Y, Zhou Y-r, Jiang Y, Melcher K, et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38:1205\u201335.","journal-title":"Acta Pharmacol Sin"},{"key":"8186_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38495-5","volume":"14","author":"C Leistner","year":"2023","unstructured":"Leistner C, Wilkinson M, Burgess A, Lovatt M, Goodbody S, Xu Y, et al. The in-tissue molecular architecture of \u03b2-amyloid pathology in the mammalian brain. Nat Commun. 2023;14:2833.","journal-title":"Nat Commun"},{"key":"8186_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2013.08.035","volume":"154","author":"J-X Lu","year":"2013","unstructured":"Lu J-X, Qiang W, Yau W-M, Schwieters CD, Meredith SC, Tycko R. Molecular structure of \u03b2-amyloid fibrils in Alzheimer\u2019s disease brain tissue. Cell. 2013;154:1257\u201368.","journal-title":"Cell"},{"key":"8186_CR18","doi-asserted-by":"crossref","unstructured":"Ghosh S, Ali R, Verma S. A\u03b2-oligomers: a potential therapeutic target for Alzheimer\u2019s disease. Int J Biol Macromol. 2023;239:124231.","DOI":"10.1016\/j.ijbiomac.2023.124231"},{"key":"8186_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","volume":"129","author":"KL Viola","year":"2015","unstructured":"Viola KL, Klein WL. Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129:183\u2013206.","journal-title":"Acta Neuropathol"},{"key":"8186_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.expneurol.2014.09.016","volume":"263","author":"C-C Chiu","year":"2015","unstructured":"Chiu C-C, Yeh T-H, Lai S-C, Wu-Chou Y-H, Chen C-H, Mochly-Rosen D, et al. Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism. Exp Neurol. 2015;263:244\u201353.","journal-title":"Exp Neurol"},{"key":"8186_CR21","doi-asserted-by":"publisher","first-page":"12924","DOI":"10.3390\/ijms232112924","volume":"23","author":"U Sehar","year":"2022","unstructured":"Sehar U, Rawat P, Reddy AP, Kopel J, Reddy PH. Amyloid beta in aging and Alzheimer\u2019s disease. Int J Mol Sci. 2022;23:12924.","journal-title":"Int J Mol Sci"},{"key":"8186_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jare.2023.01.006","volume":"54","author":"FJ Rodriguez-Jimenez","year":"2023","unstructured":"Rodriguez-Jimenez FJ, Ure\u00f1a-Peralta J, Jendelova P, Erceg S. Alzheimer\u2019s disease and synapse loss: what can we learn from induced pluripotent stem Cells?. J Adv Res. 2023;54:105\u201318.","journal-title":"J Adv Res"},{"key":"8186_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.celrep.2013.08.042","volume":"5","author":"P Nilsson","year":"2013","unstructured":"Nilsson P, Loganathan K, Sekiguchi M, Matsuba Y, Hui K, Tsubuki S, et al. A\u03b2 secretion and plaque formation depend on autophagy. Cell Rep. 2013;5:61\u201369.","journal-title":"Cell Rep"},{"key":"8186_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2023.103903","volume":"127","author":"RS Revol","year":"2023","unstructured":"Revol RS, Koistinen NA, Menon PK, Chicote-Gonz\u00e0lez A, Iverfeldt K, Str\u00f6m A-L. Alpha-secretase dependent nuclear localization of the amyloid-\u03b2 precursor protein-binding protein Fe65 promotes DNA repair. Mol Cell Neurosci. 2023;127:103903.","journal-title":"Mol Cell Neurosci"},{"key":"8186_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ph11010012","volume":"11","author":"R Peron","year":"2018","unstructured":"Peron R, Vatanabe IP, Manzine PR, Camins A, Cominetti MR. Alpha-secretase ADAM10 regulation: insights into Alzheimer\u2019s disease treatment. Pharmaceuticals. 2018;11:12.","journal-title":"Pharmaceuticals"},{"key":"8186_CR26","doi-asserted-by":"crossref","unstructured":"Al-Kuraishy HM, Jabir MS, Al-Gareeb AI, Albuhadily AK, Albukhaty S, Sulaiman GM, et al. Evaluation and targeting of amyloid precursor protein (APP)\/amyloid beta (A\u03b2) axis in amyloidogenic and non-amyloidogenic pathways: a time outside the tunnel. Ageing Res Rev. 2023;92:102119.","DOI":"10.1016\/j.arr.2023.102119"},{"key":"8186_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/14728222.2020.1737012","volume":"24","author":"E Lauretti","year":"2020","unstructured":"Lauretti E, Pratic\u00f2 D. Alzheimer\u2019s disease: phenotypic approaches using disease models and the targeting of tau protein. Expert Opin Ther Targets. 2020;24:319\u201330.","journal-title":"Expert Opin Ther Targets"},{"key":"8186_CR28","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.neurobiolaging.2014.02.011","volume":"35","author":"A Di Meco","year":"2014","unstructured":"Di Meco A, Joshi YB, Pratic\u00f2 D. Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer\u2019s disease with plaques and tangles. Neurobiol Aging. 2014;35:1813\u201320.","journal-title":"Neurobiol Aging"},{"key":"8186_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pneurobio.2008.03.002","volume":"85","author":"J-Z Wang","year":"2008","unstructured":"Wang J-Z, Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol. 2008;85:148\u201375.","journal-title":"Prog Neurobiol"},{"key":"8186_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuroscience.2022.05.023","volume":"518","author":"JS Jim\u00e9nez","year":"2023","unstructured":"Jim\u00e9nez JS. Macromolecular structures and proteins interacting with the microtubule associated tau protein. Neuroscience. 2023;518:70\u201382.","journal-title":"Neuroscience"},{"key":"8186_CR31","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2174\/156720510793611592","volume":"7","author":"K Iqbal","year":"2010","unstructured":"Iqbal K, Liu F, Gong C-X, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010;7:656\u201364.","journal-title":"Curr Alzheimer Res"},{"key":"8186_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/jcb.10133","volume":"85","author":"GA Farias","year":"2002","unstructured":"Farias GA, Mu\u00f1oz JP, Garrido J, Maccioni RB. Tubulin, actin, and tau protein interactions and the study of their macromolecular assemblies. J Cell Biochem. 2002;85:315\u201324.","journal-title":"J Cell Biochem"},{"key":"8186_CR33","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1096\/fj.08-121590","volume":"23","author":"L Amniai","year":"2009","unstructured":"Amniai L, Barbier P, Sillen A, Wieruszeski J-M, Peyrot V, Lippens G, et al. Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules. FASEB J. 2009;23:1146\u201352.","journal-title":"FASEB J"},{"key":"8186_CR34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","volume":"133","author":"T Guo","year":"2017","unstructured":"Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol. 2017;133:665\u2013704.","journal-title":"Acta Neuropathol"},{"key":"8186_CR35","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/alz.12321","volume":"17","author":"CM Moloney","year":"2021","unstructured":"Moloney CM, Lowe VJ, Murray ME. Visualization of neurofibrillary tangle maturity in Alzheimer\u2019s disease: a clinicopathologic perspective for biomarker research. Alzheimer\u2019s Dement. 2021;17:1554\u201374.","journal-title":"Alzheimer\u2019s Dement"},{"key":"8186_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-019-0675-9","volume":"7","author":"KR Christensen","year":"2019","unstructured":"Christensen KR, Beach TG, Serrano GE, Kanaan NM. Pathogenic tau modifications occur in axons before the somatodendritic compartment in mossy fiber and Schaffer collateral pathways. Acta Neuropathol Commun. 2019;7:1\u201321.","journal-title":"Acta Neuropathol Commun"},{"key":"8186_CR37","doi-asserted-by":"crossref","unstructured":"Gao Y-L, Wang N, Sun F-R, Cao X-P, Zhang W, Yu J-T. Tau in neurodegenerative disease. Ann Transl Med. 2018;6:175.","DOI":"10.21037\/atm.2018.04.23"},{"key":"8186_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/B978-0-12-819410-2.00022-9","volume":"184","author":"S Pelucchi","year":"2022","unstructured":"Pelucchi S, Gardoni F, Di Luca M, Marcello E. Synaptic dysfunction in early phases of Alzheimer\u2019s disease. Handb Clin Neurol. 2022;184:417\u201338.","journal-title":"Handb Clin Neurol"},{"key":"8186_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/alz.12192","volume":"17","author":"AF Arnsten","year":"2021","unstructured":"Arnsten AF, Datta D, Del Tredici K, Braak H. Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2021;17:115\u201324.","journal-title":"Alzheimer\u2019s Dement"},{"key":"8186_CR40","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.neuron.2011.11.033","volume":"73","author":"A De Calignon","year":"2012","unstructured":"De Calignon A, Polydoro M, Su\u00e1rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, et al. Propagation of tau pathology in a model of early Alzheimer\u2019s disease. Neuron. 2012;73:685\u201397.","journal-title":"Neuron"},{"key":"8186_CR41","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3233\/JAD-201077","volume":"79","author":"MJ Ben\u00edtez","year":"2021","unstructured":"Ben\u00edtez MJ, Cuadros R, Jim\u00e9nez JS. Phosphorylation and dephosphorylation of tau protein by the catalytic subunit of PKA, as probed by electrophoretic mobility retard. J Alzheimer\u2019s Dis. 2021;79:1143\u201356.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"8186_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","volume":"6","author":"U Sengupta","year":"2016","unstructured":"Sengupta U, Nilson AN, Kayed R. The role of amyloid-\u03b2 oligomers in toxicity, propagation, and immunotherapy. EBioMedicine. 2016;6:42\u201349.","journal-title":"EBioMedicine"},{"key":"8186_CR43","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3390\/cells12101386","volume":"12","author":"W Araki","year":"2023","unstructured":"Araki W. A\u03b2 oligomer toxicity-reducing therapy for the prevention of Alzheimer\u2019s disease: importance of the Nrf2 and PPAR\u03b3 pathways. Cells. 2023;12:1386.","journal-title":"Cells"},{"key":"8186_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-018-0453-0","volume":"11","author":"YC Youn","year":"2019","unstructured":"Youn YC, Kang S, Suh J, Park YH, Kang MJ, Pyun J-M, et al. Blood amyloid-\u03b2 oligomerization associated with neurodegeneration of Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther. 2019;11:1\u20138.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"8186_CR45","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12551-023-01052-x","volume":"15","author":"IY Petrushanko","year":"2023","unstructured":"Petrushanko IY, Mitkevich VA, Makarov AA. Effect of \u03b2-amyloid on blood-brain barrier properties and function. Biophys Rev. 2023;15:183\u201397.","journal-title":"Biophys Rev"},{"key":"8186_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00401-016-1558-9","volume":"132","author":"KR Sadleir","year":"2016","unstructured":"Sadleir KR, Kandalepas PC, Buggia-Pr\u00e9vot V, Nicholson DA, Thinakaran G, Vassar R. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A\u03b2 generation in Alzheimer\u2019s disease. Acta Neuropathol. 2016;132:235\u201356.","journal-title":"Acta Neuropathol"},{"key":"8186_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106150","volume":"182","author":"R Mabrouk","year":"2023","unstructured":"Mabrouk R, Miettinen P, Tanila H. Most dystrophic neurites in the common 5xFAD Alzheimer mouse model originate from axon terminals. Neurobiol Dis. 2023;182:106150.","journal-title":"Neurobiol Dis"},{"key":"8186_CR48","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41593-020-00783-4","volume":"24","author":"C Escartin","year":"2021","unstructured":"Escartin C, Galea E, Lakatos A, O\u2019Callaghan JP, Petzold GC, Serrano-Pozo A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021;24:312\u201325.","journal-title":"Nat Neurosci"},{"key":"8186_CR49","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/glia.23943","volume":"69","author":"MV Sanchez-Mico","year":"2021","unstructured":"Sanchez-Mico MV, Jimenez S, Gomez-Arboledas A, Mu\u00f1oz-Castro C, Romero-Molina C, Navarro V, et al. Amyloid\u2014\u03b2 impairs the phagocytosis of dystrophic synapses by astrocytes in Alzheimer\u2019s disease. Glia. 2021;69:997\u20131011.","journal-title":"Glia"},{"key":"8186_CR50","doi-asserted-by":"publisher","first-page":"170228","DOI":"10.1098\/rsob.170228","volume":"7","author":"GR Frost","year":"2017","unstructured":"Frost GR, Li Y-M. The role of astrocytes in amyloid production and Alzheimer\u2019s disease. Open Biol. 2017;7:170228.","journal-title":"Open Biol"},{"key":"8186_CR51","doi-asserted-by":"crossref","unstructured":"Patani R, Hardingham GE, Liddelow SA. Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. Nat Rev Neurol 2023;19:395\u201309.","DOI":"10.1038\/s41582-023-00822-1"},{"key":"8186_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41583-022-00641-1","volume":"24","author":"AN Brandebura","year":"2023","unstructured":"Brandebura AN, Paumier A, Onur TS, Allen NJ. Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders. Nat Rev Neurosci. 2023;24:23\u201339.","journal-title":"Nat Rev Neurosci"},{"key":"8186_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/srep27812","volume":"6","author":"D Briley","year":"2016","unstructured":"Briley D, Ghirardi V, Woltjer R, Renck A, Zolochevska O, Taglialatela G, et al. Preserved neurogenesis in non-demented individuals with AD neuropathology. Sci Rep. 2016;6:27812.","journal-title":"Sci Rep"},{"key":"8186_CR54","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1002\/alz.13074","volume":"19","author":"B Tumurbaatar","year":"2023","unstructured":"Tumurbaatar B, Fracassi A, Scaduto P, Guptarak J, Woltjer R, Jupiter D, et al. Preserved autophagy in cognitively intact non-demented individuals with Alzheimer\u2019s neuropathology. Alzheimer\u2019s Dement. 2023;19:5355\u201370.","journal-title":"Alzheimer\u2019s Dement"},{"key":"8186_CR55","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12035-020-01868-8","volume":"57","author":"O Zolochevska","year":"2020","unstructured":"Zolochevska O, Taglialatela G. Selected microRNAs increase synaptic resilience to the damaging binding of the Alzheimer\u2019s disease amyloid beta oligomers. Mol Neurobiol. 2020;57:2232\u201343.","journal-title":"Mol Neurobiol"},{"key":"8186_CR56","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3233\/JAD-180179","volume":"65","author":"O Zolochevska","year":"2018","unstructured":"Zolochevska O, Bjorklund N, Woltjer R, Wiktorowicz JE, Taglialatela G. Postsynaptic proteome of non-demented individuals with Alzheimer\u2019s disease neuropathology. J Alzheimer\u2019s Dis. 2018;65:659\u201382.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"8186_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-023-02679-6","volume":"147","author":"M Colom-Cadena","year":"2024","unstructured":"Colom-Cadena M, Toombs J, Simzer E, Holt K, McGeachan R, Tulloch J, et al. Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer\u2019s disease. Acta Neuropathol. 2024;147:1\u201322.","journal-title":"Acta Neuropathol"},{"key":"8186_CR58","doi-asserted-by":"publisher","first-page":"e041782","DOI":"10.1002\/alz.041782","volume":"16","author":"M Colom-Cadena","year":"2020","unstructured":"Colom-Cadena M, Tulloch J, Rose J, Smith C, Spires-Jones T. TMEM97 is a potential amyloid beta receptor in human Alzheimer\u2019s disease synapses: Human neuropathology\/amyloid. Alzheimer\u2019s Dement. 2020;16:e041782.","journal-title":"Alzheimer\u2019s Dement"},{"key":"8186_CR59","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/jb\/mvy022","volume":"163","author":"T Kaizuka","year":"2018","unstructured":"Kaizuka T, Takumi T. Postsynaptic density proteins and their involvement in neurodevelopmental disorders. J Biochem. 2018;163:447\u201355.","journal-title":"J Biochem"},{"key":"8186_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49537-9","volume":"13","author":"T Katano","year":"2023","unstructured":"Katano T, Konno K, Takao K, Abe M, Yoshikawa A, Miyakawa T, et al. Brain-enriched guanylate kinase-associated protein, a component of the post-synaptic density protein complexes, contributes to learning and memory. Sci Rep. 2023;13:22027.","journal-title":"Sci Rep"},{"key":"8186_CR61","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/cm.21822","volume":"81","author":"K Iqbal","year":"2024","unstructured":"Iqbal K. Tau and Alzheimer\u2019s disease: past, present and future. Cytoskeleton. 2024;81:116\u201321.","journal-title":"Cytoskeleton"},{"key":"8186_CR62","doi-asserted-by":"publisher","first-page":"23645","DOI":"10.1074\/jbc.M703269200","volume":"282","author":"DP Hanger","year":"2007","unstructured":"Hanger DP, Byers HL, Wray S, Leung K-Y, Saxton MJ, Seereeram A, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem. 2007;282:23645\u201354.","journal-title":"J Biol Chem"},{"key":"8186_CR63","doi-asserted-by":"crossref","unstructured":"Su J, Xiao Y, Wei L, Lei H, Sun F, Wang W, et al. Generation of tau dephosphorylation-targeting chimeras for the treatment of Alzheimer\u2019s disease and related tauopathies. Sci Bull 2024;69:1137\u201352.","DOI":"10.1016\/j.scib.2024.01.019"},{"key":"8186_CR64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3233\/JAD-2009-0960","volume":"16","author":"H-C Huang","year":"2009","unstructured":"Huang H-C, Jiang Z-F. Accumulated amyloid-\u03b2 peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2009;16:15\u201327.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"8186_CR65","doi-asserted-by":"publisher","first-page":"24374","DOI":"10.1016\/S0021-9258(20)80536-5","volume":"268","author":"E K\u00f6pke","year":"1993","unstructured":"K\u00f6pke E, Tung Y-C, Shaikh S, Alonso AdC, Iqbal K, Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem. 1993;268:24374\u201384.","journal-title":"J Biol Chem"},{"key":"8186_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99932-3","volume":"11","author":"S Khamse","year":"2021","unstructured":"Khamse S, Jafarian Z, Bozorgmehr A, Tavakoli M, Afshar H, Keshavarz M, et al. Novel implications of a strictly monomorphic (GCC) repeat in the human PRKACB gene. Sci Rep. 2021;11:20629.","journal-title":"Sci Rep"},{"key":"8186_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fsb2.21134","volume":"34","author":"R Liu","year":"2020","unstructured":"Liu R, Wang L-l, Jiang H-l. MicroRNA-200a-3p mediates neuroprotection in Alzheimer-related deficits and attenuates amyloid-beta overproduction and tau hyperphosphorylation via co-regulating BACE1 and PRKACB. FASEB J. 2020;34:1.","journal-title":"FASEB J"},{"key":"8186_CR68","doi-asserted-by":"crossref","unstructured":"Matrone C, Petrillo F, Nasso R, Ferretti G. Fyn tyrosine kinase as harmonizing factor in neuronal functions and dysfunctions. Int J Mol Sci 2020;21:4444.","DOI":"10.3390\/ijms21124444"},{"key":"8186_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104668","volume":"134","author":"T Rush","year":"2020","unstructured":"Rush T, Roth JR, Thompson SJ, Aldaher AR, Cochran JN, Roberson ED. A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-\u03b2 toxicity. Neurobiol Dis. 2020;134:104668.","journal-title":"Neurobiol Dis"},{"key":"8186_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-017-0176-x","volume":"12","author":"T Miyamoto","year":"2017","unstructured":"Miyamoto T, Stein L, Thomas R, Djukic B, Taneja P, Knox J, et al. Phosphorylation of tau at Y18, but not tau-fyn binding, is required for tau to modulate NMDA receptor-dependent excitotoxicity in primary neuronal culture. Mol Neurodegener. 2017;12:1\u201319.","journal-title":"Mol Neurodegener"},{"key":"8186_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00636-1","volume":"18","author":"SP Yu","year":"2023","unstructured":"Yu SP, Jiang MQ, Shim SS, Pourkhodadad S, Wei L. Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer\u2019s disease. Mol Neurodegener. 2023;18:43.","journal-title":"Mol Neurodegener"},{"key":"8186_CR72","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-022-05534-y","volume":"613","author":"NB McNamara","year":"2023","unstructured":"McNamara NB, Munro DA, Bestard-Cuche N, Uyeda A, Bogie JF, Hoffmann A, et al. Microglia regulate central nervous system myelin growth and integrity. Nature. 2023;613:120\u20139.","journal-title":"Nature"},{"key":"8186_CR73","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13108","volume":"33","author":"A Fracassi","year":"2023","unstructured":"Fracassi A, Marcatti M, Tumurbaatar B, Woltjer R, Moreno S, Taglialatela G. TREM2-induced activation of microglia contributes to synaptic integrity in cognitively intact aged individuals with Alzheimer\u2019s neuropathology. Brain Pathol. 2023;33:e13108.","journal-title":"Brain Pathol"},{"key":"8186_CR74","doi-asserted-by":"publisher","first-page":"12353","DOI":"10.1074\/jbc.H120.015304","volume":"295","author":"SF Lichtenthaler","year":"2020","unstructured":"Lichtenthaler SF, Meinl E. To cut or not to cut: New rules for proteolytic shedding of membrane proteins. J Biol Chem. 2020;295:12353\u20135.","journal-title":"J Biol Chem"},{"key":"8186_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42505-x","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Tang L, Yang J, Meng L, Chen J, Zhou L, et al. Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer\u2019s disease. Nat Commun. 2023;14:6670.","journal-title":"Nat Commun"},{"key":"8186_CR76","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jamda.2022.10.001","volume":"24","author":"W Liu","year":"2023","unstructured":"Liu W, Xing S, Wei F, Yao Y, Zhang H, Li Y-C, et al. Excessive dietary salt intake exacerbates cognitive impairment progression and increases dementia risk in older adults. J Am Med Dir Assoc. 2023;24:125\u20139.e124.","journal-title":"J Am Med Dir Assoc"},{"key":"8186_CR77","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41586-019-1688-z","volume":"574","author":"G Faraco","year":"2019","unstructured":"Faraco G, Hochrainer K, Segarra SG, Schaeffer S, Santisteban MM, Menon A, et al. Dietary salt promotes cognitive impairment through tau phosphorylation. Nature. 2019;574:686\u201390.","journal-title":"Nature"},{"key":"8186_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2024.109570","volume":"125","author":"HC Chen","year":"2024","unstructured":"Chen HC, Cao J-X, Zhang Y-S, Ma Y-Z, Zhang L, Su X-M, et al. High salt diet exacerbates cognitive deficits and neurovascular abnormalities in APP\/PS1 mice and induces AD-like changes in wild-type mice. J Nutr Biochem. 2024;125:109570.","journal-title":"J Nutr Biochem"},{"key":"8186_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109504","volume":"114","author":"W Yang","year":"2023","unstructured":"Yang W, Xu Q-Q, Yuan Q, Xian Y-F, Lin Z-X. Sulforaphene, a CDK5 Inhibitor, attenuates cognitive deficits in a transgenic mouse model of Alzheimer\u2019s disease via reducing A\u03b2 Deposition, tau hyperphosphorylation and synaptic dysfunction. Int Immunopharmacol. 2023;114:109504.","journal-title":"Int Immunopharmacol"},{"key":"8186_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1078987","volume":"9","author":"R Shukla","year":"2023","unstructured":"Shukla R, Kumar A, Kelvin DJ, Singh TR. Disruption of DYRK1A-induced hyperphosphorylation of amyloid-beta and tau protein in Alzheimer\u2019s disease: an integrative molecular modeling approach. Front Mol Biosci. 2023;9:1078987.","journal-title":"Front Mol Biosci"},{"key":"8186_CR81","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00018-020-03626-4","volume":"78","author":"AJ Laham","year":"2021","unstructured":"Laham AJ, Saber-Ayad M, El-Awady R. DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis. Cell Mol Life Sci. 2021;78:603\u201319.","journal-title":"Cell Mol Life Sci"},{"key":"8186_CR82","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.nbd.2017.06.010","volume":"106","author":"S Garc\u00eda-Cerro","year":"2017","unstructured":"Garc\u00eda-Cerro S, Rueda N, Vidal V, Lantigua S, Mart\u00ednez-Cu\u00e9 C. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer\u2019s disease phenotypes. Neurobiol Dis. 2017;106:76\u201388.","journal-title":"Neurobiol Dis"},{"key":"8186_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175633","volume":"947","author":"Z Li","year":"2023","unstructured":"Li Z, Chen R, Li Y, Zhou Q, Zhao H, Zeng K, et al. A comprehensive overview of PPM1B: From biological functions to diseases. Eur J Pharm. 2023;947:175633.","journal-title":"Eur J Pharm"},{"key":"8186_CR84","doi-asserted-by":"crossref","unstructured":"Lee YH, Im E, Hyun M, Park J, Chung KC. Protein phosphatase PPM1B inhibits DYRK1A kinase through dephosphorylation of pS258 and reduces toxic tau aggregation. J Biol Chem. 2021;296:100245.","DOI":"10.1074\/jbc.RA120.015574"},{"key":"8186_CR85","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1111\/j.1460-9568.2005.04391.x","volume":"22","author":"F Liu","year":"2005","unstructured":"Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci. 2005;22:1942\u201350.","journal-title":"Eur J Neurosci"},{"key":"8186_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115245","volume":"251","author":"RL Arribas","year":"2023","unstructured":"Arribas RL, Viejo L, Bravo I, Mart\u00ednez M, Ramos E, Romero A, et al. C-glycosides analogues of the okadaic acid central fragment exert neuroprotection via restoration of PP2A-phosphatase activity: A rational design of potential drugs for Alzheimer\u2019s disease targeting tauopathies. Eur J Medi Chem. 2023;251:115245.","journal-title":"Eur J Medi Chem"},{"key":"8186_CR87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.arr.2012.06.008","volume":"12","author":"L Martin","year":"2013","unstructured":"Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin M-L, Terro F. Tau protein phosphatases in Alzheimer\u2019s disease: the leading role of PP2A. Ageing Res Rev. 2013;12:39\u201349.","journal-title":"Ageing Res Rev"},{"key":"8186_CR88","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1096\/fj.10-158477","volume":"24","author":"X Wang","year":"2010","unstructured":"Wang X, Blanchard J, Kohlbrenner E, Clement N, Linden RM, Radu A, et al. The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB J. 2010;24:4420.","journal-title":"FASEB J"},{"key":"8186_CR89","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1021\/acs.jnatprod.2c01153","volume":"86","author":"Z Ju","year":"2023","unstructured":"Ju Z, Shang Z, Mahmud T, Fang J, Liu Y, Pan Q, et al. Synthesis and anti-inflammatory activity of the natural cyclooxygenase-2 inhibitor axinelline a and its analogues. J Nat Products. 2023;86:958\u201365.","journal-title":"J Nat Products"},{"key":"8186_CR90","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s11481-019-09896-5","volume":"15","author":"Q-L Ling","year":"2020","unstructured":"Ling Q-L, Akasaka H, Chen C, Haile CN, Winoske K, Ruan K-H. The protective effects of up-regulating prostacyclin biosynthesis on neuron survival in hippocampus. J Neuroimmune Pharmacol. 2020;15:292\u2013308.","journal-title":"J Neuroimmune Pharmacol"},{"key":"8186_CR91","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41589-020-0553-6","volume":"16","author":"S Rajan","year":"2020","unstructured":"Rajan S, Jang Y, Kim C-H, Kim W, Toh HT, Jeon J, et al. PGE1 and PGA1 bind to Nurr1 and activate its transcriptional function. Nat Chem Biol. 2020;16:876\u201386.","journal-title":"Nat Chem Biol"},{"key":"8186_CR92","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s13311-018-00704-1","volume":"16","author":"G-B Xu","year":"2019","unstructured":"Xu G-B, Yang L-Q, Guan P-P, Wang Z-Y, Wang P. Prostaglandin A1 inhibits the cognitive decline of APP\/PS1 transgenic mice via PPAR\u03b3\/ABCA1-dependent cholesterol efflux mechanisms. Neurotherapeutics. 2019;16:505\u201322.","journal-title":"Neurotherapeutics"},{"key":"8186_CR93","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s12035-020-02174-z","volume":"58","author":"G-B Xu","year":"2021","unstructured":"Xu G-B, Guan P-P, Wang P. Prostaglandin A1 decreases the phosphorylation of tau by activating protein phosphatase 2A via a michael addition mechanism at cysteine 377. Mol Neurobiol. 2021;58:1114\u201327.","journal-title":"Mol Neurobiol"},{"key":"8186_CR94","doi-asserted-by":"publisher","first-page":"26971","DOI":"10.1074\/jbc.M704059200","volume":"282","author":"S Longin","year":"2007","unstructured":"Longin S, Zwaenepoel K, Louis JV, Dilworth S, Goris J, Janssens V. Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic subunit. J Biol Chem. 2007;282:26971\u201380.","journal-title":"J Biol Chem"},{"key":"8186_CR95","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1016\/j.celrep.2019.11.044","volume":"29","author":"EK Pickett","year":"2019","unstructured":"Pickett EK, Herrmann AG, McQueen J, Abt K, Dando O, Tulloch J, et al. Amyloid beta and tau cooperate to cause reversible behavioral and transcriptional deficits in a model of Alzheimer\u2019s disease. Cell Rep. 2019;29:3592\u2013604.e3595.","journal-title":"Cell Rep"},{"key":"8186_CR96","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche MA, Hyman BT. Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat Neurosci. 2020;23:1183\u201393.","journal-title":"Nat Neurosci"},{"key":"8186_CR97","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41593-018-0289-8","volume":"22","author":"MA Busche","year":"2019","unstructured":"Busche MA, Wegmann S, Dujardin S, Commins C, Schiantarelli J, Klickstein N, et al. Tau impairs neural circuits, dominating amyloid-\u03b2 effects, in Alzheimer models in vivo. Nat Neurosci. 2019;22:57\u201364.","journal-title":"Nat Neurosci"},{"key":"8186_CR98","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1021\/acschemneuro.9b00037","volume":"10","author":"T Tripathi","year":"2019","unstructured":"Tripathi T, Kalita P. Synergistic effect of amyloid-\u03b2 and tau disrupts neural circuits. ACS Chem Neurosci. 2019;10:1129\u201330.","journal-title":"ACS Chem Neurosci"},{"key":"8186_CR99","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1126\/science.1062097","volume":"293","author":"J Gotz","year":"2001","unstructured":"Gotz J, Chen FV, Van Dorpe J, Nitsch R. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A\u03b242 fibrils. Science. 2001;293:1491\u20135.","journal-title":"Science"},{"key":"8186_CR100","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-018-1953-5","volume":"137","author":"C Vergara","year":"2019","unstructured":"Vergara C, Houben S, Suain V, Yilmaz Z, De Decker R, Vanden Dries V, et al. Amyloid-\u03b2 pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo. Acta Neuropathol. 2019;137:397\u2013412.","journal-title":"Acta Neuropathol"},{"key":"8186_CR101","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/nn.4328","volume":"19","author":"JW Wu","year":"2016","unstructured":"Wu JW, Hussaini SA, Bastille IM, Rodriguez GA, Mrejeru A, Rilett K, et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat Neurosci. 2016;19:1085\u201392.","journal-title":"Nat Neurosci"},{"key":"8186_CR102","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1093\/brain\/awad189","volume":"146","author":"DN Schoonhoven","year":"2023","unstructured":"Schoonhoven DN, Coomans EM, Mill\u00e1n AP, Van Nifterick AM, Visser D, Ossenkoppele R, et al. Tau protein spreads through functionally connected neurons in Alzheimer\u2019s disease: a combined MEG\/PET study. Brain. 2023;146:4040\u201354.","journal-title":"Brain"},{"key":"8186_CR103","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.neuron.2022.03.034","volume":"110","author":"WJ Lee","year":"2022","unstructured":"Lee WJ, Brown JA, Kim HR, La Joie R, Cho H, Lyoo CH, et al. Regional A\u03b2-tau interactions promote onset and acceleration of Alzheimer\u2019s disease tau spreading. Neuron. 2022;110:1932\u201343.e1935.","journal-title":"Neuron"},{"key":"8186_CR104","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.tins.2022.11.006","volume":"46","author":"KM Igarashi","year":"2023","unstructured":"Igarashi KM. Entorhinal cortex dysfunction in Alzheimer\u2019s disease. Trends Neurosci. 2023;46:124\u201336.","journal-title":"Trends Neurosci"},{"key":"8186_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-016-0143-y","volume":"12","author":"Y Wang","year":"2017","unstructured":"Wang Y, Balaji V, Kaniyappan S, Kr\u00fcger L, Irsen S, Tepper K, et al. The release and trans-synaptic transmission of Tau via exosomes. Mol Neurodegener. 2017;12:1\u201325.","journal-title":"Mol Neurodegener"},{"key":"8186_CR106","doi-asserted-by":"publisher","first-page":"12445","DOI":"10.1074\/jbc.M115.709485","volume":"291","author":"JC Polanco","year":"2016","unstructured":"Polanco JC, Scicluna BJ, Hill AF, G\u00f6tz J. Extracellular vesicles isolated from the brains of rTg4510 mice seed tau protein aggregation in a threshold-dependent manner. J Biol Chem. 2016;291:12445\u201366.","journal-title":"J Biol Chem"},{"key":"8186_CR107","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/ijms19030663","volume":"19","author":"FX Guix","year":"2018","unstructured":"Guix FX, Corbett GT, Cha DJ, Mustapic M, Liu W, Mengel D, et al. Detection of aggregation-competent tau in neuron-derived extracellular vesicles. Int J Mol Sci. 2018;19:663.","journal-title":"Int J Mol Sci"},{"key":"8186_CR108","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/s41374-021-00644-z","volume":"101","author":"E Miyoshi","year":"2021","unstructured":"Miyoshi E, Bilousova T, Melnik M, Fakhrutdinov D, Poon WW, Vinters HV, et al. Exosomal tau with seeding activity is released from Alzheimer\u2019s disease synapses, and seeding potential is associated with amyloid beta. Lab Investig. 2021;101:1605\u201317.","journal-title":"Lab Investig"},{"key":"8186_CR109","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00401-018-1868-1","volume":"136","author":"M Sardar Sinha","year":"2018","unstructured":"Sardar Sinha M, Ansell-Schultz A, Civitelli L, Hildesj\u00f6 C, Larsson M, Lannfelt L, et al. Alzheimer\u2019s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers. Acta Neuropathol. 2018;136:41\u201356.","journal-title":"Acta Neuropathol"},{"key":"8186_CR110","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.neurobiolaging.2014.02.012","volume":"35","author":"MB Dinkins","year":"2014","unstructured":"Dinkins MB, Dasgupta S, Wang G, Zhu G, Bieberich E. Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer\u2019s disease. Neurobiol Aging. 2014;35:1792\u2013800.","journal-title":"Neurobiol Aging"},{"key":"8186_CR111","doi-asserted-by":"crossref","unstructured":"Chintamaneni PK, Pindiprolu SS, Krishnamurthy PT, Varshni MS. Targeted drug delivery: amyloid beta targeting drugs, immunotherapy, anti-tau and aggregation inhibitor, microtubule-stabilizing, and neuroinflammation modulation. In Multi-Factorial Approach as a Therapeutic Strategy for the Management of Alzheimer\u2019s Disease 2025;237\u201358.","DOI":"10.1007\/978-981-96-0259-9_12"},{"key":"8186_CR112","doi-asserted-by":"crossref","unstructured":"Paul JK, Malik A, Azmal M, Gulzar T, Afghan MTR, Talukder OF, et al. Advancing Alzheimer\u2019s therapy: computational strategies and treatment innovations. IBRO Neurosci Rep. 2025;18:270\u201382.","DOI":"10.1016\/j.ibneur.2025.02.002"},{"key":"8186_CR113","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24:399\u2013416.","journal-title":"Nat Rev Immunol"},{"key":"8186_CR114","doi-asserted-by":"crossref","unstructured":"Cullen NC, Novak P, Tosun D, Kovacech B, Hanes J, Kontsekova E, et al. Efficacy assessment of an active tau immunotherapy in Alzheimer\u2019s disease patients with amyloid and tau pathology: a post hoc analysis of the \u201cADAMANT\u201d randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial. EBioMedicine.2024;99:104923.","DOI":"10.1016\/j.ebiom.2023.104923"},{"key":"8186_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11940-025-00827-9","volume":"27","author":"N Aderinto","year":"2025","unstructured":"Aderinto N, Abraham IC, Olatunji G, Kokori E, Ashinze P, Babawale EA, et al. Vaccine based approaches for the prevention and treatment of neurological disease. Curr Treat Options Neurol. 2025;27:1\u201314.","journal-title":"Curr Treat Options Neurol"},{"key":"8186_CR116","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","volume":"3","author":"R Vandenberghe","year":"2017","unstructured":"Vandenberghe R, Riviere M-E, Caputo A, Sovago J, Maguire RP, Farlow M, et al. Active A\u03b2 immunotherapy CAD106 in Alzheimer\u2019s disease: a phase 2b study. Alzheimer\u2019s Dement. 2017;3:10\u201322.","journal-title":"Alzheimer\u2019s Dement"},{"key":"8186_CR117","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40263-019-00613-7","volume":"33","author":"B Das","year":"2019","unstructured":"Das B, Yan R. A close look at BACE1 inhibitors for Alzheimer\u2019s disease treatment. CNS drugs. 2019;33:251\u201363.","journal-title":"CNS drugs"},{"key":"8186_CR118","doi-asserted-by":"crossref","unstructured":"Kaur N, Gupta S, Pal J, Bansal Y, Bansal G. Design of BBB permeable BACE-1 inhibitor as potential drug candidate for Alzheimer Disease: 2D-QSAR, molecular docking, ADMET, molecular dynamics, MMGBSA. Comput Biol Chem. 2025;116:108371.","DOI":"10.1016\/j.compbiolchem.2025.108371"},{"key":"8186_CR119","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/alz.13532","volume":"20","author":"ME Riviere","year":"2024","unstructured":"Riviere ME, Langbaum JB, Turner RS, Rinne JO, Sui Y, Cazorla P, et al. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE \u03b54 homozygotes. Alzheimer\u2019s Dement. 2024;20:1839\u201350.","journal-title":"Alzheimer\u2019s Dement"},{"key":"8186_CR120","doi-asserted-by":"publisher","first-page":"453","DOI":"10.14283\/jpad.2023.27","volume":"10","author":"T Walsh","year":"2023","unstructured":"Walsh T, Duff L, Riviere M-E, Tariot P, Doak K, Smith M, et al. Outreach, screening, and randomization of APOE \u03b54 carriers into an Alzheimer\u2019s prevention trial: a global perspective from the API generation program. J Prev Alzheimer\u2019s Dis. 2023;10:453\u201363.","journal-title":"J Prev Alzheimer\u2019s Dis"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08186-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:09:19Z","timestamp":1768165759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08186-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8186"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08186-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}